Literature DB >> 2682463

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.

A P Albino1, D M Nanus, I R Mentle, C Cordon-Cardo, N S McNutt, J Bressler, M Andreeff.   

Abstract

This study examined noncultured and cultured melanomas and related precursor specimens for (i) mutated ras genes using polymerase chain reaction (PCR) methodology, (ii) correlation of mutated ras genes with differentiation related phenotypic characteristics, (iii) expression of ras-encoded p21 proteins in tissues by immunoperoxidase analysis, (iv) quantitative expression of mutated and wild-type ras encoded p21 proteins by flow cytometry, and (v) correlation between p21 expression, the occurrence of ras mutations, and cell cycle kinetics. The results of these studies are (1) 24% of cultured malignant melanomas have activated ras genes, with N-ras being activated ten times as frequently as Harvey (Ha)-ras. Each example of an activated ras gene showed a mutation at the 61st codon of the protein, with the exception of one melanoma which showed a mutation at codon 13 of the N-ras gene; (2) all the melanomas displaying an activated ras gene had a similar cell surface phenotype and appear to come from a similar phase of differentiation; (3) 5-6% of noncultured primary and metastatic melanomas have mutated ras genes; (4) no ras gene mutations were found in any precursor lesion, specifically normal nevi and dysplastic nevi; (5) immunoperoxidase analysis of paraffin-embedded specimens indicated no quantitative or qualitative alterations in p21 expression that correlate with tumor progression; (6) there were no observable differences in p21 expression between melanoma cells growing exponentially or in plateau phase, or between melanoma cells with or without ras mutations; nor were any cell kinetic differences found between cells with and without mutated ras genes. These studies suggest that the role of ras mutations may be limited to an indirect involvement in the transformation of a subset of melanomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682463

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Asymmetric distribution of oncogene products at mitosis.

Authors:  B Czerniak; F Herz; R P Wersto; L G Koss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 3.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Changes in protein expression during melanoma differentiation determined by computer analysis of 2-D gels.

Authors:  D Easty; I R Hart; K Patel; C Seymour; M Yacoub; A Domscheit; S Gunther; W Postel; A Gorg; M J Dunn
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

5.  Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Authors:  Julie A Ellerhorst; Victoria R Greene; Suhendan Ekmekcioglu; Carla L Warneke; Marcella M Johnson; Carolyn P Cooke; Li-E Wang; Victor G Prieto; Jeffrey E Gershenwald; Qingyi Wei; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

Review 6.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

7.  msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation.

Authors:  T Shioda; M H Fenner; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

8.  A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.

Authors:  M Nakamura; M Katano; K Fujimoto; T Morisaki
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

Review 9.  Melanoma: new insights and new therapies.

Authors:  Vasiliki A Nikolaou; Alexander J Stratigos; Keith T Flaherty; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

10.  Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.

Authors:  Michael Dovey; Richard Mark White; Leonard I Zon
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.